07:41 AM EST, 11/04/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q3 net loss Tuesday of $0.94 per diluted share, widening from a loss of $0.82 a year earlier.

Analysts polled by FactSet expected a loss of $0.68.

Collaboration revenue for the quarter ended Sept. 30 was $2.8 million, compared with $3.7 million a year earlier.

As of Sept. 30, Kymera Therapeutics ( KYMR ) said it had $978.7 million in cash, cash equivalents and investments, which it expects to provide it with a cash runway into H2 2028.